Clinicians are recommended to construct an initial regimen (for first time therapy) by choosing one component from Column A plus one component from Column B*
Column A Column B
 
NNRTI PI
2-NRTI
Preferred (alphabetical order)
Efavirenz 1

Atazanavir + ritonavir

Fosamprenavir + ritonavir (twice daily)

Lopinavir/ritonavir (twice daily)

Abacavir/ lamivudine 3 (for patients who test negative for HLA-B*5701)

Tenofovir/ emtricitabine 3
Alternative (alphabetical order)
Nevirapine 2

Atazanavir 4 (unboosted)

Fosamprenavir (unboosted)

Fosamprenavir + ritonavir once daily

Lopinavir/ritonavir once daily

Saquinavir + ritonavir

(in order of preference)

Zidovudine/ lamivudine

Didanosine + lamivudine 3

 

 
  1. Except during first trimester of pregnancy or in women with high pregnancy potential
  2. Nevirapine should not be initiated in women with CD4+ T-cell count greater than 250 cells/mm3 or in men with CD4+ T-cell count greater than 400 cells/mm3
  3. Emtricitabine and lamivudine are interchangeable
  4. Atazanavir must be boosted with ritonavir if used in combination with tenofovir

Editor’s note: Above drug names are generic. Please refer to the individual drug pages for brand names, or visit www.tpan.com

* Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services. January 29, 2008; 1–136. Available here. Accessed March 14, 2008; page 63, Table 6a. Call 1-800-HIV-0440 (448-0440)


back to top